

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q58461

Hans Berg ANDREASEN, et al.

Appln. No.: 09/509,681

Group Art Unit: 1615

Confirmation No.: 3146

Examiner: Todd Ware

Filed: March 30, 2000

For: A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND,  
☐ IRON-DEXTRAN COMPOUND PRODUCED ACCORDING TO SAID PROCESS,  
☐ PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF  
☐ IRON-DEFICIENCY AND USE OF SAID COMPOUND FOR THE .....


**SUBMISSION OF TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith is a Terminal Disclaimer in the above-identified application. A check in the amount of \$110.00 is attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this Submission is attached.

Respectfully submitted,



Terrance J. Wikberg  
Registration No. 47,177

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: March 3, 2004

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q58461

Hans Berg ANDREASEN, et al.

Appln. No.: 09/509,681

Group Art Unit: 1615

Confirmation No.: 3146

Examiner: Todd Ware

Filed: March 30, 2000

For: A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND,  
☐ IRON-DEXTRAN COMPOUND PRODUCED ACCORDING TO SAID PROCESS,  
☐ PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF  
☐ IRON-DEFICIENCY AND USE OF SAID COMPOUND FOR THE .....

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned, on behalf of the petitioner, PHARMACOSMOS HOLDING A/S, represents that the petitioner, PHARMACOSMOS HOLDING A/S is the owner of the entire right, title and interest of U.S. Application No. 09/509,454, filed on March 29, 2000 for IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINSTRABLE THERAPEUTICAL COMPOSITION by virtue of an Assignment from all of the inventors thereof executed on March 3, 2000, recorded on March 29, 2000 at Reel 010809, Frame 0043, now issued as U.S. Patent 6,291,440 as well as the entire right, title and interest in the above-

Terminal Disclaimer  
U.S. Patent Application Ser. No.: 09/509,681

captioned U.S. Application No. 09/509,681 by virtue of an Assignment from all of the inventors thereof executed on March 3, 2000, recorded on March 30, 2000, at Reel 010808, Frame 0398.

Petitioner hereby certifies that the above-mentioned Assignments have been reviewed and to the best of petitioner's knowledge and belief, title is in petitioner who is seeking to take this action.

Petitioner hereby disclaims the terminal part of any patent granted on the above-captioned U.S. Application No. 09/509,681 which would extend beyond the expiration of the full statutory term as presently shortened by any terminal disclaimer of U.S. Patent 6,291,440, and hereby agrees that any patent so granted on the above-captioned U.S. Application No. 09/509,681 shall be enforceable only for and during such period that the legal title to U.S. Patent 6,291,440 shall be the same as the legal title to said patent issuing from the above-captioned U.S. Application No. 09/509,681, this agreement to run with any patent granted on the above-captioned U.S. Application No. 09/509,681 and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-captioned U.S. Application No. 09/509,681 prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of U.S. Patent 6,291,440 in the event that U.S. Patent 6,291,440 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a Reexamination Certificate, or is otherwise terminated


Terminal Disclaimer

U.S. Patent Application Ser. No.: 09/509,681

prior to the expiration of its statutory term as presently shortened by any terminal disclaimer,  
except for the separation of legal title stated above.

The undersigned whose signature and title appear below is empowered to act on behalf of  
petitioner.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Brian W. Hannon", written over a horizontal line.

Brian W. Hannon

Registration No. 32,778

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: March 3, 2004